用于口服颗粒 (迷你片) 的释放测试策略,使儿科药物的安全和有效供应成为可能
Anna Externbrink1, Andreas Abend2, Elizabeth Galella3
1MSD, Schachen, Luzern 6003, Switzerland.
Journal of pharmaceutical sciences
|November 2, 2025
概括
制药公司正在开发小儿迷你药片,灵感来自PREA和BPCA等法规. 本研究提出了这些儿科药物配方的高效释放测试策略,以确保质量和可访问性.
科学领域:
- 制药科学 制药科学
- 儿科药物开发 儿科药物开发
- 配方技术 配方技术 配方技术
背景情况:
- 欧盟第1901/2006条例和儿科研究公平性和儿童最佳药品法案 (PREA和BPCA) 刺激了儿科药物配方的开发.
- 迷你片被青为儿科固体口服剂型由于高可接受性,剂量灵活性和稳定性超过液体配方.
- 对儿科药物的需求较低,导致分配给释放测试的批次比例不成比例.
研究的目的:
- 为了应对儿科药物开发中的经济挑战.
- 确保儿童群体持续获得高质量的药物.
- 为各种剂量强度的迷你药片配方开发灵活有效的释放测试策略.
主要方法:
- 讨论特定于迷你片剂剂型的关键质量属性 (CQAs).
- 分析数据以支持合理化的释放测试策略.
- 考虑经济因素和监管鼓励儿童药物开发.
主要成果:
- 确定迷你平板电脑发布所必需的关键质量属性.
- 关于优化释放测试的数据驱动方法的建议.
- 强调有效策略对于具有成本效益的儿科药物开发的重要性.
结论:
- 灵活和高效的释放测试策略对于儿科迷你平板电脑至关重要.
- 解决经济和质量方面的考虑对于儿科医学的可访问性至关重要.
- 智商联盟的工作为儿童药物开发中释放测试的合理化提供了一个框架.
相关概念视频
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
201
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
201
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
296
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
296
01:18Drug Delivery: Enteral Route
1.5K
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
1.5K
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
142
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
142
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
239
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
239
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
249
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
249